Connecticut Wealth Management LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Rating) in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 2,013 shares of the biotechnology company's stock, valued at approximately $223,000.

Several other hedge funds have also made changes to their positions in the business. Wellington Management Group LLP boosted its stake in shares of Sarepta Therapeutics by 33.6% during the first quarter. Wellington Management Group LLP now owns 2,680,478 shares of the biotechnology company's stock worth $209,399,000 after buying an additional 673,725 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in Sarepta Therapeutics by 2.4% during the second quarter. Price T Rowe Associates Inc. MD now owns 1,163,847 shares of the biotechnology company's stock worth $87,242,000 after purchasing an additional 27,042 shares in the last quarter. Bellevue Group AG raised its holdings in Sarepta Therapeutics by 39.2% during the first quarter. Bellevue Group AG now owns 1,151,159 shares of the biotechnology company's stock worth $89,929,000 after purchasing an additional 324,418 shares in the last quarter. Assenagon Asset Management S.A. raised its holdings in Sarepta Therapeutics by 154.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,129,016 shares of the biotechnology company's stock worth $124,801,000 after purchasing an additional 685,845 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in Sarepta Therapeutics by 3.6% during the first quarter. Federated Hermes Inc. now owns 703,583 shares of the biotechnology company's stock worth $54,964,000 after purchasing an additional 24,609 shares in the last quarter. Institutional investors and hedge funds own 87.31% of the company's stock.

Wall Street Analyst Weigh In

SRPT has been the subject of several analyst reports. The Goldman Sachs Group increased their price target on shares of Sarepta Therapeutics from $152.00 to $171.00 and gave the stock a "buy" rating in a report on Thursday, November 3rd. BTIG Research increased their price target on shares of Sarepta Therapeutics from $125.00 to $160.00 and gave the stock a "buy" rating in a report on Thursday, December 22nd. Needham & Company LLC increased their price target on shares of Sarepta Therapeutics from $158.00 to $160.00 and gave the stock a "buy" rating in a report on Tuesday, January 10th. Cowen increased their target price on shares of Sarepta Therapeutics from $114.00 to $125.00 in a report on Wednesday, January 11th. Finally, Robert W. Baird increased their target price on shares of Sarepta Therapeutics from $110.00 to $152.00 in a report on Thursday, November 3rd. Three equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $149.07.

Insider Buying and Selling at Sarepta Therapeutics

Sarepta Therapeutics Stock Up 2.6 %

Shares of NASDAQ SRPT opened at $130.00 on Wednesday. Sarepta Therapeutics, Inc. has a 1 year low of $61.28 and a 1 year high of $134.08. The firm's 50 day moving average price is $120.58 and its 200 day moving average price is $109.79. The firm has a market cap of $11.41 billion, a P/E ratio of -15.83 and a beta of 1.04. The company has a debt-to-equity ratio of 3.58, a quick ratio of 3.99 and a current ratio of 4.36.

Sarepta Therapeutics (NASDAQ:SRPT – Get Rating) last announced its earnings results on Wednesday, November 2nd. The biotechnology company reported ($2.94) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.21) by ($1.73). The firm had revenue of $230.30 million for the quarter, compared to analyst estimates of $234.55 million. Sarepta Therapeutics had a negative return on equity of 97.37% and a negative net margin of 81.76%. The firm's revenue was up 21.6% compared to the same quarter last year. During the same quarter last year, the business posted ($0.60) EPS. As a group, sell-side analysts anticipate that Sarepta Therapeutics, Inc. will post -8.19 earnings per share for the current year.

Sarepta Therapeutics Profile

(Get Rating)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping.

Further Reading

• Get a free copy of the StockNews.com research report on Sarepta Therapeutics (SRPT)
• J.B. Hunt Gets A Flat, Logistic Companies Come Into Focus
• Is Intel Stock On The Verge Of Breaking Out?
• Does it Matter Folks Aren't "Starry-Eyed" Over Pepsi's New Soda?
• Johnson & Johnson Breakout Breaks Down: Can Earnings Boost Stock?
• Can Alaska Air Continue Soaring Above The Airline Industry?

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.